Research Article

circ_0001588 Induces the Malignant Progression of Hepatocellular Carcinoma by Modulating miR-874/CDK4 Signaling

Xiaoyun Bin,1 Yichen Chen,2 Jiasheng Ma,2 Renchao Tang,2 Zhenrong Zhao,2 Kangxuan Wang,2 and Jianchu Wang 2

1College of Basic Medical Sciences, Youjiang Medical University for Nationalities, Baise, China
2Department of Hepatobiliary Surgery, Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, China

Correspondence should be addressed to Jianchu Wang; wjianchu@sina.com

Received 28 May 2021; Accepted 25 August 2021; Published 20 October 2021

Academic Editor: Sainan Li

Copyright © 2021 Xiaoyun Bin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Accumulating evidence indicates that circular RNAs (circRNAs) can interact with microRNAs to modulate gene expression in various cancers, including hepatocellular carcinoma (HCC). Although the significant role of circRNAs has been well documented in HCC, the complex mechanisms of circRNAs still need to be elucidated. Our current study is aimed at investigating the function of circ_0001588 in HCC, which was observed to significantly increase in HCC tissues and cells. We demonstrated that the knockdown of circ_0001588 resulted in repressed cell proliferation, migration, and invasion. In vivo studies using a nude mouse model showed that circ_0001588 downregulation reduced tumor size. Moreover, miR-874 was predicted as a target of circ_0001588. Using luciferase binding assays, we proved that circ_0001588 functions as a molecular ceRNA of miR-874 and that CDK4 acts as a downstream target of miR-874 in HCC. It was confirmed that overexpression of miR-874 decreased the proliferation, migration, and invasion triggered by the increase in circ_0001588. In summary, our results indicate that circ_0001588 acts as a ceRNA and promotes HCC progression by targeting the miR-874/CDK4 signaling pathway. Hence, we propose that circ_0001588 may be a promising target for HCC treatment.

1. Introduction

Hepatocellular carcinoma (HCC) accounts for 90% of primary liver carcinomas worldwide [1, 2] and is a leading cause of malignant tumors in humans with high morbidity and mortality rates [3, 4]. Although great advances have been made in the therapeutic strategies for HCC treatment, attempts to increase the average 5-year survival rate of HCC patients remain unsatisfactory [5]. To date, little is known about the pathogenesis of HCC. Hence, it is crucial to understand the pathology of HCC and identify the underlying mechanisms.

Circular RNAs (circRNAs) have been reported to play significant roles in various cell activities [6–8]. Several studies have shown that circRNAs can regulate multiple tumor processes such as cell proliferation, apoptosis, migration, and invasion [9–11]. For example, circRNA BCRC-3 can repress bladder cancer development by regulating miR-182-5p and p27 [12]. circ_100395 regulates miR-1228 and TCF21 to inhibit lung cancer development [13], and circRNA UBAP2 can induce ovarian cancer progression by sponging miR-144 [14].

circRNAs are important biomarkers for HCC. It has been reported that circRNAs can demonstrate oncogenic or suppressive effects on HCC development by regulating various biological processes [15, 16]. For example, circRHOT1 promotes HCC progression through the initiation of NR2F6 [17], circTRIM33-12 serves as a sponge for miR-191 to repress HCC progression [18]. circ_0001588, located on chromosome 6, has been reported to be abnormally highly expressed in lung adenocarcinoma [19]. However, its biological role and molecular mechanisms in HCC remain poorly understood.
In this study, we aimed to investigate the mechanism of circ_0001588 in contributing to the malignant phenotypes of HCC.

2. Materials and Methods

2.1. Cell Culture. Human HCC cell lines used in this study (SK-Hep-1, Hep-3B, HepG2, BEL-7402, and MHCC-LM3) and the control hepatic normal cell line (LO2) were obtained from the Shanghai Institute of Cell Biology, Chinese Academy of Sciences (Shanghai, China). Cells were incubated in DMEM medium (Gibco, Grand Island, NY, USA) supplemented with 10% heat-inactivated FBS, 1% penicillin (100 U/mL), and 0.1 mg/mL streptomycin in a humidified chamber with 5% CO₂ and 95% air at 37°C.

2.2. Plasmid Construction and Cell Transfection. To overexpress circ_0001588, the full-length circ_0001588 cDNA was amplified in HCC cells and then cloned into the overexpression vector pLCDH-ciR (Genechem, Shanghai, China). All plasmids were isolated using a DNA Midiprep kit (Qiagen, Hilden, Germany). To perform miR-874 overexpression and knockdown, miR-874 mimics, miR-874 inhibitor, and two scrambled miRNAs used as negative controls were purchased (Genechem). Transfections were performed using the Lipofectamine® 3000 reagent (Invitrogen, Waltham, MA, USA).

2.3. CCK-8 Assay. The transfected cells were seeded into 96-well plates at a density of 1 × 10⁴ cells per well. A Cell Counting Kit-8 (A311-01, Vazyme, Nanjing, China) was used to measure cell proliferation.

Table 1: Primers for real-time PCR.

| Genes        | Forward (5‘-3’)                | Reverse (5‘-3’)                |
|--------------|--------------------------------|--------------------------------|
| GAPDH        | GCACCGTCAAGGGTGGAAC            | TGGTGAACCGCAGTGGA              |
| circ_0001588 | GGTGTCAAGGGCATTTCTGG          | GACGCTTACGGCTCCTTTTA          |
| CDK4         | TGAATTTGTTGCTGGCTGCTT          | CAGTCGGAATCTAAAGGCA           |
| miR-874      | GAACTCCACTGTAGCA              | CATTTTTCCACTCTCTCTCTCTCA      |
| U6           | CTGCCTTCGCAGCACA              | AACGCTTACGAATTTGCTG           |

Figure 1: Increase of circ_0001588 expression in HCC cells. (a) Expression of circ_0001588 in HCC cells (SK-Hep-1, Hep-3B, HepG2, BEL-7402, and MHCC-LM3) and LO2 cells. (b, c) The expressions of circ_0001588 were measured in HepG2 and BEL-7402 cells using RT-qPCR. Cells were infected with LV-NC or LV-shcirc_0001588. *P < 0.05.
Figure 2: Continued.
Figure 2: circ_0001588 exerted oncogenic effects on HCC cells. (a) The growth curves were measured by CCK-8 assays. (b) Cell apoptosis was tested using flow cytometry. (c) Cell cycle distribution was assessed using flow cytometry. (d, e) Cell migration and invasion assays were carried out in HCC cells. Scale bar = 100 μm. *P < 0.05.

Figure 3: circ_0001588 promoted the growth of liver cancer xenograft. (a) Subcutaneous transplantation of HepG2 cells with silenced circ_0001588 in BALB/c nude mice. Tumor volume was measured every 3 days (volume = width² × length × 1/2). (b) Tumor volume when the mice were sacrificed. (c) After 22 days, the xenograft tumors were excised from the nude mice. The relative weights of tumors were analyzed. (d) HE staining of the xenograft tumor tissues. (e) Ki-67 in the xenograft tumors was examined by flow cytometry. *P < 0.05.
Relative microRNA expression of folds

HepG2

BEL-7402

Relative RNA enrichment

HepG2

BEL-7402

Relative luciferase activity

WT Circ_0001588 5'-CUGCGAGAUAACAUCCAGGGCAU-3'
mir-874 3'-AGCCAGGGAGCCCGGUCCCGUC-5'
MUT Circ_0001588 5'-CUGCGAGAUAACUGUCCCGGU-3'

Figure 4: Continued.
used to detect cell viability. Absorbance was measured at 450 nm using a microplate reader.

2.4. Detection of Apoptosis and Cell Cycle. Cell apoptosis and cell cycle phase distribution indicated by cellular DNA content were analyzed by flow cytometry. HCC cells were harvested, washed with cold PBS, fixed in 70% ethanol, and treated with 10 mg/mL RNase A. Fixed cells were stained with PI dye followed by incubation in the dark. The PI fluorescence of individual nuclei was measured using a flow cytometer (BD FACSCalibur, Becton Dickinson, Franklin Lakes, NJ, USA). The data were analyzed using Cell Quest Pro V 3.2.1 software (Becton Dickinson).

2.5. Transwell Migration and Invasion Assay. To carry out the invasion experiment, Matrigel was diluted to 1 mg/mL on ice using a precooled serum-free medium; 40 μL per well was added to a Transwell chamber. Then, 100 μL and 600 μL of serum-free medium were added to the upper and lower chambers, respectively, and equilibrated overnight at 37°C. 100 μL of the cell suspension and 600 μL of complete medium were added to the Transwell chamber. The upper chamber was placed in a culture well. After incubation for 48 h, the upper chamber was removed. Crystal violet (0.1% concentration; 500 μL) was added to a 24-well plate. The chamber was placed, and the membrane was immersed in the medium at 37°C for 30 min. Finally, five fields of view diameters were selected, imaged, and counted. To carry out the migration experiment, the cells were incubated in the Transwell chamber for 24 h. The other steps were the same as those used for the invasion assay.

2.6. Western Blotting. Cells were washed and proteins were extracted using lysis buffer (100 μL/50 mL). Protein samples were separated using SDS-PAGE and transferred to polyvinylidene fluoride membranes (Millipore, Burlington, MA, USA). Membranes were incubated with anti-CDK4 and GAPDH primary antibodies (Abcam, Cambridge, UK). The next day, the membranes were incubated at room temperature with a horseradish peroxidase-labeled secondary antibody (Santa Cruz Technology, Santa Cruz, CA, USA) for 1 h. Membranes were visualized using an enhanced chemiluminescence (ECL) system.

2.7. RT-PCR. Total RNA was extracted using the TRIzol reagent (Invitrogen). For miRNA analysis, cDNA was obtained using the TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems, Waltham, MA, USA). qRT-PCR was conducted using the TaqMan miRNA assay kit (Applied Biosystems). For mRNA analysis, cDNA was synthesized using M-MLV reverse transcriptase (Invitrogen) and reverse transcription primer Oligo(dT). Then, qRT-PCR was carried out using SYBR Green Real-Time PCR Master Mix (Thermo Fisher Scientific, Waltham, MA, USA) on a 7900HT Fast Real-Time PCR machine (Applied Biosystems). The primers used are listed in Table 1.

2.8. Luciferase Reporter Analysis. Cells were seeded in 24-well plates overnight. Luciferase reporters including circ_0001588-WT, circ_0001588-MUT, CDK4-WT, and CDK4-MUT were constructed by Genechem. A QuikChange Lightning kit (Stratagene, La Jolla, CA, USA) was used to perform site-directed mutagenesis. Sequencing was performed to confirm the correct mutations. Luciferase activity was measured using the dual-luciferase reporter assay system (Promega, Madison, WI, USA).

2.9. RNA Immunoprecipitation Assay. Cells (~1 × 10^7) were washed with cold PBS and lysed with RIP lysis buffer (EMD Millipore). Cell lysates were incubated with RIP immunoprecipitation buffer containing magnetic beads conjugated with human Ago2 antibody (Millipore) or negative control mouse IgG (Millipore). Extracted RNAs were analyzed.
HepG2

(a)

BEL-7402

(b)

Figure 5: Continued.
using qRT-PCR to test for the presence of circ_0001588 and miR-874.

2.10. Animal Studies. Twelve BALB/c, all-female nude mice (6–8 weeks old) were obtained from the Chinese Science Academy (Shanghai, China). Mice were injected with 5 × 10⁶ WT HepG2 cells (control) or circ_0001588 shRNA-transfected HepG2 cells (12 nude mice were randomly divided into 2 groups, 6 in each group). The growth of implanted HCC tumors was monitored for their volumes every 5 days up to 22 days postinoculation. Xenograft tumor size was recorded every three days (volume = width² × length × 1/2). Tumors were fixed in 10% formalin, embedded in paraffin, and cut into 4 μm thick slices. Hematoxylin and eosin staining was used to observe the tumor histology. Animal procedures were performed according to the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The assays were approved by the Animal Care and Use Committee of the Affiliated Hospital of Youjiang Medical University for Nationalities.

2.11. Flow Cytometry of Ki-67 Analysis. To test the frequencies of Ki-67 positive cells, tumor cells were fixed, permeabilized, and stained with anti-Ki-67-FITC (BD Biosciences, Franklin Lakes, NJ, USA). Cells stained with fluorophore-conjugated secondary antibodies were analyzed by flow cytometry.

2.12. Statistical Analysis. Data were analyzed using the SPSS software (version 19.0). All experiments were conducted in triplicate, and the values are presented as the mean ± SEM. Two-tailed Student’s t-test was used to analyze the statistical differences between the two groups. Multiple groups were compared using a one-way analysis of variance. Statistical significance was set at P < 0.05.

3. Results

3.1. circ_0001588 Is Upregulated in HCC Cells. To identify the expression levels of circ_0001588 in HCC, as shown in Figure 1(a), we observed that the expression of circ_0001588 in HCC cells (SK-Hep-1, Hep-3B, HepG2, BEL-7402, and MHCC-LM3) was also more elevated compared to that in LO2 cells. A potential association between circ_0001588 and HCC was demonstrated. Further, we identified the detailed function of circ_0001588 in HCC cells by using shRNA to silence circ_0001588. As displayed in Figures 1(b) and 1(c), circ_0001588 expression was greatly reduced by circ_0001588 shRNA in HCC cells.

3.2. circ_0001588 Exerts a Vital Role in HCC’s Oncogenesis. Proliferation of cells in which circ_0001588 was silenced was analyzed using the CCK-8 test. We found that HCC cell growth was decreased in circ_0001588 shRNA-transfected cells compared to that in the control cells (Figure 2(a)). HCC cell apoptosis was induced by the lack of circ_0001588, while cell cycle progression was blocked by circ_0001588 shRNA (Figures 2(b) and 2(c)). Migration and invasion studies indicated that circ_0001588 downregulation decreased HepG2 and BEL-7402 migration and invasion capacity (Figures 2(d) and 2(e)). The above data indicate the potential role of circ_0001588 in tumorigenesis through the regulation of proliferation, migration, invasion, and apoptosis in HCC cells.

3.3. circ_0001588 Promotes the Growth of Liver Cancer Xenograft. We developed a BALB/c nude mouse model to study the role of circ_0001588 in HCC. Initially, circ_0001588 was inhibited in HepG2 cells transplanted subcutaneously into nude mice. Tumor growth was monitored for 22 days (Figure 3(a)), showing a decrease in the volume of the tumors in the circ_0001588 shRNA group. The tumor volume was significantly reduced by circ_0001588 shRNA (Figure 3(b)). It was evident that the tumor weight decreased significantly in the group of mice with inhibited circ_0001588 (Figure 3(c)). We assessed the tumors isolated 22 days after implantation using H&E and Ki-67 assays (Figures 3(d) and 3(e)), showing that the Ki-67 positive cell ratio was reduced in the circ_0001588 shRNA group, indicating a slower proliferation when compared with sh-NC.
Figure 6: Continued.
3.4. circ_0001588 Targets miR-874. To further understand circ_0001588 binding targets, we analyzed the circ_0001588 overexpressing cells and found that miR-874 exhibited the lowest expression in the circ_0001588 overexpressing cells (Figures 4(a) and 4(b)). We performed a RNA immunoprecipitation assay with an anti-Argonaute2 (Ago2) antibody to pull down circ_0001588 and miR-874 using anti-Ago2 antibodies or control IgG. We observed that circ_0001588 and miR-874 were significantly pulled down with anti-Ago2 antibodies in HCC cells (Figures 4(c) and 4(d)). Additionally, we performed a luciferase binding assay, wherein labeling vectors were designed for circ_0001588 WT and MUT vectors (Figure 4(e)) with appropriate luciferase labeling. It was evident (Figures 4(f) and 4(g)) that, in the presence of miR-218-5p, in the cells expressing circ_0001588 wild-type, there was a significant decrease in the luciferase activity compared to the control (mimics-NC), while inhibitors exhibited increased luciferase activity.

3.5. miR-874 Interacts with and Regulates CDK4 Expression. We found that CDK4 expression was significantly reduced by miR-874 mimics in HCC cells (Figures 5(a) and 5(b)) and identified CDK4 as an important target of miR-874. To assess the binding capacity between them, we designed vectors for the wild-type 3'-UTR of CDK4 and a mutant 3'-UTR of CDK4 with mutations at the predicted miR-874 binding sites (Figure 5(c)). As shown in Figures 5(d) and 5(e), a significant decrease in luciferase activity was observed in cells cotransfected with the wild-type 3'-UTR of CDK4 and miR-874 mimics; there was no decrease in luciferase activity in cells expressing mutant CDK4. CDK4 expression was negatively regulated by miR-874 mimics in HCC cells (Figures 5(f) and 5(g)).

3.6. circ_0001588 Promotes the Progression of HCC via Targeting miR-874 and CDK4 Pathway. To understand the interplay between circ_0001588, miR-874, and CDK4, HCC cells were infected with circ_0001588-OE and miR-874 mimics. As shown in Figures 6(a) and 6(b), we found that circ_0001588 overexpression increased the expression of CDK4 that was reversed by miR-874 mimics in HCC cells. Additionally, we observed that circ_0001588 overexpression enhanced HCC cell proliferation, while overexpression of miR-874 reduced cell proliferation (Figures 6(c) and 6(d)). Apoptosis of HCC cells was inhibited by circ_0001588 overexpression, while miR-874 mimics triggered cell apoptosis (Figures 6(e) and 6(f)). We have shown that induced HCC migration and invasion capacity by circ_0001588 were reversed by the overexpression of miR-874 (Figures 6(g) and 6(h)). This further strengthens our evidence of the significant role of circ_0001588 and miR-874 in HCC progression.

4. Discussion

In this study, we observed that circ_0001588 expression was increased in HCC. To the best of our knowledge, this is the first report on elevated circ_0001588 expression in HCC. circ_0001588 induces the progression of lung cancer by modulating miR-524-3p and NACC1 signaling [20]. Here, we found that the loss of circ_0001588 suppressed the malignant behavior of HCC cells. Hence, circ_0001588 may be a therapeutic target for HCC; our data may shed new light on the pathogenesis of HCC.

circRNAs bind to their targeted microRNAs and act as ceRNAs to sponge the corresponding microRNAs and repress their activity [21, 22]. For example, circRNA_0084043 promotes melanoma progression by regulating miR-153-3p and the Snail axis [23]. Dysregulated circRNA_100876 represses the proliferation of osteosarcoma cancer cells by targeting miR-136 [24]. circMTO1 serves as a sponge for miR-9 to inhibit HCC progression [25]. In our study, miR-874 was predicted to be a target of circ_0001588; miR-874 has been recognized as a tumor suppressor in HCC. For example, miR-874 inhibits HCC proliferation and metastasis by targeting DOR/EGFR/ERK signaling [26]. miR-874 suppresses metastasis and EMT in HCC by
targeting SOX12 [27]. We have demonstrated that miR-874 is downregulated in HCC and observed a negative correlation between miR-874 and circ_0001588. Our findings provide new insights into the molecular regulation of circ_0001588 in HCC.

Moreover, miR-874 targets serine-threonine kinase cyclin-dependent kinase 4 (CDK4), a tumor oncogene. CDK4 is a pivotal cell cycle regulator that triggers an important cascade of events in the G1-phase by efficiently catalyzing Rb phosphorylation [28, 29]. The CDK 4/6-inhibitor of CDK4- (INK4-) retinoblastoma (Rb) pathway controls cell cycle progression by regulating the G1-S checkpoint [30, 31]. Palbociclib is a selective CDK4/6 inhibitor that restricts tumor growth in preclinical models of HCC [32]. We have determined the relationship between miR-874 and CDK4 expression in HCC in this study. CDK4 expression in HCC cells was negatively regulated by miR-874; miR-328-5p over-expression inhibited CD4 expression, which was induced by circ_0001588. Future studies should investigate the correlation between circ_0001588 and CDK4.

In summary, we have indicated that circ_0001588 acts as a tumor oncogene to induce HCC progression. We observed that circ_0001588 effectively sponged miR-874 that targeted CDK4. The loss of circ_0001588 significantly reduced HCC tumor growth in vivo by regulating miR-874 and CDK4. Hence, the circ_0001588/miR-874/CDK4 pathway may be critical for treating HCC.

**Data Availability**

The data used to support the findings of this study are included within the article.

**Conflicts of Interest**

The authors declare no financial or commercial conflict of interest.

**Authors’ Contributions**

JW, XB, YC, and JM designed and revised the study; XB, YC, and JM performed the research; RT, ZZ, and KW collected the data and did the analysis; XB prepared the manuscript draft; JW revised the MS. All authors approved the final manuscript. Xiaoyun Bin, Yichen Chen, and Jiasheng Ma contributed equally to this work.

**Acknowledgments**

This work was supported by the Guangxi clinic medicine research center of hepatobiliary diseases (grant number AD17129025).

**References**

[1] European Association for the Study of the Liver and European Organisation for Research and Treatment of Cancer, “EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma,” *European Journal of Cancer*, vol. 48, no. 5, pp. 599–641, 2012.

[2] A. P. Venook, C. Papandreou, J. Furuse, and L. L. de Guevara, “The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective,” *The Oncologist*, vol. 15, Suppl 4, pp. 5–13, 2010.

[3] L. Y. Mak, V. Cruz-Ramón, P. Chinchilla-Lopez et al., “Global epidemiology, prevention, and management of hepatocellular carcinoma,” *American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting*, vol. 38, pp. 262–279, 2018.

[4] S. A. Kishore, R. Bajwa, and D. C. Madoff, “Embolo- therapeutic strategies for hepatocellular carcinoma: 2020 update,” *Cancers*, vol. 12, no. 4, p. 791, 2020.

[5] R. S. Oliveri, J. Wetterres, and C. Glaud, “Hepatocellular carcinoma,” *Lancet*, vol. 380, no. 9840, p. 470, 2012.

[6] K. K. Ebbesen, T. B. Hansen, and J. Kjems, “Insights into circular RNA biology,” *RNA Biology*, vol. 14, no. 8, pp. 1035–1045, 2017.

[7] H. Zhang, Y. Shen, Z. Li et al., “The biogenesis and biological functions of circular RNAs and their molecular diagnostic values in cancers,” *Journal of Clinical Laboratory Analysis*, vol. 34, no. 1, article e23049, 2020.

[8] J. E. Wilusz, “A 360° view of circular RNAs: from biogenesis to functions,” *Wiley interdisciplinary reviews. RNA*, vol. 9, no. 4, article e1478, 2018.

[9] T. Yu, Y. Wang, Y. Fan et al., “CircRNAs in cancer metabolism: a review,” *Journal of Hematology & Oncology*, vol. 12, no. 1, p. 90, 2019.

[10] I. L. Patop and S. Kadener, “circRNAs in cancer,” *Current Opinion in Genetics & Development*, vol. 48, pp. 121–127, 2018.

[11] L. S. Kristensen, T. B. Hansen, M. T. Veno, and J. Kjems, “Circular RNAs in cancer: opportunities and challenges in the field,” *Oncogene*, vol. 37, no. 5, pp. 555–565, 2018.

[12] F. Xie, Y. Li, M. Wang et al., “Circular RNA BCRC-3 suppresses bladder cancer proliferation through miR-182-5p/p27 axis,” *Molecular Cancer*, vol. 17, no. 1, p. 144, 2018.

[13] D. Chen, W. Ma, Z. Ke, and F. Xie, “CircRNA hsa_circ_001395 regulates miR-1228/TGF21 pathway to inhibit lung cancer progression,” *Cell Cycle*, vol. 17, no. 16, pp. 2080–2090, 2018.

[14] M. Sheng, N. Wei, H. Y. Yang, M. Yan, Q. X. Zhao, and L. J. Jing, “CircRNA UBAP2 promotes the progression of ovarian cancer by sponging microRNA-144,” *European Review for Medical and Pharmacological Sciences*, vol. 23, no. 17, pp. 7283–7294, 2019.

[15] L. Qiu, H. Xu, M. Ji et al., “Circular RNAs in hepatocellular carcinoma: biomarkers, functions and mechanisms,” *Life Sciences*, vol. 231, p. 116660, 2019.

[16] M. Wang, F. Yu, and P. Li, “Circular RNAs: characteristics, function and clinical significance in hepatocellular carcinoma,” *Cancers*, vol. 10, no. 8, p. 258, 2018.

[17] L. Wang, H. Long, Q. Zheng, X. Bo, X. Xiao, and B. Li, “Circular RNA circRHT1 promotes hepatocellular carcinoma progression by initiation of NR2F6 expression,” *Molecular Cancer*, vol. 18, no. 1, p. 119, 2019.

[18] P. F. Zhang, C. Y. Wei, X. Y. Huang et al., “Circular RNA circTRIM33-12 acts as the sponge of microRNA-191 to suppress hepatocellular carcinoma progression,” *Molecular Cancer*, vol. 18, no. 1, p. 105, 2019.

[19] Y. Xu, J. Yu, Z. Huang et al., “Circular RNA hsa_circ_000326 acts as a miR-338-3p sponge to facilitate lung adenocarcinoma
progression,” *Journal of experimental & clinical cancer research*: CR, vol. 39, no. 1, p. 57, 2020.

[20] Z. Sun, “Circular RNA hsa_circ_0001588 promotes the malignant progression of lung adenocarcinoma by modulating miR-524-3p/NACC1 signaling,” *Life Sciences*, vol. 259, p. 118157, 2020.

[21] X. Li, L. Yang, and L. L. Chen, “The biogenesis, functions, and challenges of circular RNAs,” *Molecular cell*, vol. 71, no. 3, pp. 428–442, 2018.

[22] L. S. Kristensen, M. S. Andersen, L. V. W. Stagsted, K. K. Ebbeisen, T. B. Hansen, and J. Kjems, “The biogenesis, biology and characterization of circular RNAs,” *Nature Reviews. Genetics*, vol. 20, no. 11, pp. 675–691, 2019.

[23] W. Luan, Y. Shi, Z. Zhou, Y. Xia, and J. Wang, “circRNA_0084043 promote malignant melanoma progression via miR-153-3p/Snail axis,” *Biochemical and biophysical research communications*, vol. 502, no. 1, pp. 22–29, 2018.

[24] J. Jin, A. Chen, W. Qiu et al., “Dysregulated circRNA_100876 suppresses proliferation of osteosarcoma cancer cells by targeting microRNA-136,” *Journal of Cellular Biochemistry*, vol. 120, no. 9, pp. 15678–15687, 2019.

[25] D. Han, J. Li, H. Wang et al., “Circular RNA circMTO1 acts as the sponge of microRNA-9 to suppress hepatocellular carcinoma progression,” *Hepatology*, vol. 66, no. 4, pp. 1151–1164, 2017.

[26] Y. Zhang, Y. Wei, X. Li et al., “MicroRNA-874 suppresses tumor proliferation and metastasis in hepatocellular carcinoma by targeting the DOR/EGFR/ERK pathway,” *Cell death & disease*, vol. 9, no. 2, 2018.

[27] T. Jiang, L. Y. Guan, Y. S. Ye, H. Y. Liu, and R. Li, “miR-874 inhibits metastasis and epithelial-mesenchymal transition in hepatocellular carcinoma by targeting,” *American Journal of Cancer Research*, vol. 7, no. 6, pp. 1310–1321, 2017.

[28] J. McCain, “First-in-class CDK4/6 inhibitor palbociclib could usher in a new wave of combination therapies for HR+, HER2- breast cancer,” *P & T: a peer-reviewed journal for formulary management*, vol. 40, no. 8, pp. 511–520, 2015.

[29] X. Wang, B. Yu, Y. Wu, R. J. Lee, and L. J. Lee, “Efficient down-regulation of CDK4 by novel lipid nanoparticle-mediated siRNA delivery,” *Anticancer Research*, vol. 31, no. 5, pp. 1619–1626, 2011.

[30] E. Hamilton and J. R. Infante, “Targeting CDK4/6 in patients with cancer,” *Cancer Treatment Reviews*, vol. 45, pp. 129–138, 2016.

[31] S. Goel, M. J. DeCristo, S. S. McAllister, and J. J. Zhao, “CDK4/6 inhibition in cancer: beyond cell cycle arrest,” *Trends in Cell Biology*, vol. 28, no. 11, pp. 911–925, 2018.

[32] J. Bollard, V. Miguela, M. Ruiz de Galarreta et al., “Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma,” *Gut*, vol. 66, no. 7, pp. 1286–1296, 2017.